We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions around GSK (GSK Plc) are marked by a mix of cautious outlooks and excitement over new product developments. Analysts anticipate a quarterly revenue decline of 3.2%, projecting earnings to drop from $9.99 billion to $9.677 billion when GSK reports its results on February 5th. Despite this, there are sentiments among some investors, like dope007, who express optimism regarding potential earnings surprises, suggesting, “Wouldn't be surprised if they beat on the earnings.” This reflects a readiness from some market participants to stay positive amidst the expected downturn.
Furthermore, GSK is making significant strides in the pharmaceutical space, especially with advancements in HIV and asthma treatments. The European Commission's recent authorization of Vocabria and Rekambys for adolescent HIV treatment is a notable milestone, alongside GSK's acceptance of regulatory filings for depemokimab, which targets asthma and chronic rhinosinusitis. As one investor observed, GSK’s strong market capitalization and ongoing advancements indicate underlying financial strength, with the comment, “GSK, with a market capitalization of $71 billion...maintaining a ‘GREAT’ financial performance,” highlighting confidence in its long-term prospects despite short-term revenue challenges. Overall, investor sentiment remains cautiously optimistic, driven by GSK's innovative pipeline amidst revenue headwinds.
Show more
GSK PLC is poised for increased earnings in 2024, aligning with market expectations, despite ongoing concerns regarding its U.S. vaccine segment amidst geopolitical challenges. With new announcements suggesting a promising pipeline, GSK has received regulatory acceptances for its treatments, including depemokimab for chronic rhinosinusitis and asthma with type 2 inflammation, which are being reviewed in major markets including Europe, Japan, and China. Notably, if approved, depemokimab will become the first ultra-long-acting biologic medicine with a six-month dosing schedule, reflecting GSK’s continued innovation in targeted treatments.
On the financial side, GSK's recent disclosures indicate a total of 4,145,945,481 voting rights following its standard reporting on share capital as of January 31, 2025. The Company’s growth trajectory appears sustainable, particularly with the development of treatments that have demonstrated efficacy in reducing hospitalizations and improving patient outcomes in recent trials. As GSK navigates regulatory approvals and market dynamics, its strategic focus on specialized therapeutics positions it favorably within the competitive biopharmaceutical landscape.
Show more
Yes good news followed by bad news, daily. |
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) |
I'll add my two pennyworth |
Interesting points made here. I'm assuming by individuals who hold significant amounts.?..the fact it has become more noteably political is intriguing. |
#743. What has that post got to do with GSK? |
Dr Biotech |
That's ok - they'll raise it again after the shareprice reaches 1500p, 1700p etc. |
Wow, I know analysts are useless but that's a big cut. |
These brokers are good for nothing at all. |
These brokers are so clever cutting price targets after the event...10yrs old could that... |
Deutsche Bank cuts target price to 1350p from 1700p |
Further falls as Tariffs hit. |
is RFK jnr's appointment likely to be acceptable to and confirmed by congress? It seems even some Republican members are extremely sceptical of the anti-vax and FDA rhetoric, believing that vaccination is probably the biggest medical advance of all time after clean drinking water. |
I had this sell off attributed to the legal difficulties currently being experienced by AZN big wigs in China,this was then followed by the appointment of a Health Secretly in the USA who is as deluded as trump. |
First UK case was jan 2020. Part of the problem with Covid whilst obviously a serious virus, was the misinformation given by the likes of Zero Hedge and reposted by useful idiots on other forums. Doing Russia's bidding, but too thick to realise. Would have helped of course if the Chinese had been more honest and open. |
Washingmachine 16 Nov '24 - 07:08 - 33722 |
And he’s still had a far better life than 99 percent .. |
Oh and Taylor swift for the teenys |
This whole USA democrat party |
Keyno - maybe burgers are the secret to a healthy long life. |
EI - you get a tick up for that one! |
Washingmachine16 Nov '24 - 07:08 - 33722 of 33722 (Filtered) |
Type | Ordinary Share |
Share ISIN | GB00BN7SWP63 |
Sector | Pharmaceutical Preparations |
Bid Price | 1,374.50 |
Offer Price | 1,375.00 |
Open | 1,387.50 |
Shares Traded | 15,529,148 |
Last Trade | 16:35:26 |
Low - High | 1,359.50 - 1,400.00 |
Turnover | 30.33B |
Profit | 4.93B |
EPS - Basic | 1.1889 |
PE Ratio | 11.56 |
Market Cap | 57.97B |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads